31/07/2025
🚨 New Milestone in Cancer Research and Precision Medicine 🚨
We are excited to announce the launch of a joint organoid research laboratory by Next&Bio and the Cancer Science Institute of Singapore (CSI Singapore) at the National University of Singapore (NUS)
This strategic collaboration aims to:
🔬 Build Asia’s largest organoid biobank from Asian cancer patients
🌏 Advance precision oncology with better population representation
💊 Develop innovative, animal-free preclinical drug testing platforms
📍 The agreement was officially signed on July 30 in Singapore, with key attendees including:
• Professor Ashok Venkitaraman, Director, CSI Singapore
• Dr. Sang-wook Park, CEO, Next&Bio
• Mr Jason Cho, Director, Next&Bio
• Representatives from K-Startup Center Singapore
💬 Prof. Venkitaraman shared:
“We are delighted to join forces with Next&Bio in this collaboration. Cancer organoids have emerged as important tools in the fight against cancer, but few currently represent the genetic diversity of cancers that occur amongst Singaporeans. The reproducible and robust creation of organoids requires a high level of expertise, which Next&Bio has already developed. So my colleagues and I believe that this research collaboration will help us to better understand Asian cancers to develop new treatments that benefit Singapore’s cancer patients.”
This partnership marks a significant step forward in inclusive and globally impactful translational cancer research.